Vascular endothelial growth factor receptor-2 inhibitor cediranib causes regression of endometriotic lesions in a rat model

• Published in: International journal of clinical and experimental pathology Vol. 8; no. 2; pp. 1165 - 1174
• Main Authors: Liu, Fang, Wang, Li, Zhang, Xian-Xia, Min, Shu-Yun, Liu, Yi-Xuan, Zuo, Zhi, Jin, Zhi-Xing, Zhu, Zhi-Ling
• Format: Journal Article
• Language: English
• Published: United States e-Century Publishing Corporation 01.01.2015
• Subjects: Animals; Cell Proliferation - drug effects; Disease Models, Animal; Endometriosis - drug therapy; Endometriosis - pathology; Female; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - pathology; Original; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Quinazolines - pharmacology; Quinazolines - therapeutic use; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors; endometriosis; Angiogenesis; vascular endothelial growth factor receptor-2; cediranib

Vascular endothelial growth factor (VEGF) receptor-2 plays an essential role in angiogenesis, and it also expressed in the glandular epithelium and stromal cells of ectopic endometrium. Cediranib is a protein tyrosine kinase inhibitor that potently inhibits VEGF receptor-2, but there is no study abo...